

PRESS RELEASE

Munich, 16 May 2024

GÖRG advises Medigene AG on a capital increase with gross issue proceeds of EUR 5.9 million

GÖRG Partnerschaft von Rechtsanwälten mbB, under the lead management of Munich partner Dr Bernt Paudtke, advised Medigene AG on a capital increase with gross proceeds of EUR 5.9 million.

Medigene AG is a biotechnology company founded in 1994 and listed on the stock exchange since 2000 with its headquarters in Martinsried near Munich and a US office in San Diego, California. The company develops highly innovative immunotherapies for the treatment of solid cancer tumours. Medigene focuses on differentiated T-cell-targeted therapeutic approaches.

The capital increase resolved on 22 April 2024 led to the issue of 4,912,531 new shares and an increase in the total number of shares to 29,475,189. 4,152,247 of the newly created shares were subscribed by shareholders as part of the rights offering. This corresponds to a subscription ratio of 84.52%. In addition, 760,284 new shares were placed with European investors. Members of the Executive Board and Supervisory Board of Medigene AG also participated in the capital increase. Following the entry of the capital increase in the commercial register of the Munich Local Court, the Company's new share capital amounts to EUR 29,475,189.00.

Medigene AG achieved a gross inflow of funds of around EUR 5.9 million with the capital measure. The transaction proceeds will serve the biotech company as a basis to advance the clinical development of the main programme MDG1015 and at the same time to enter into new partnerships in order to expand the end-to-end platform to further therapeutic approaches.

Medigene AG once again relied on the proven transaction team led by GÖRG partner Dr Bernt Paudtke for the capital increase. The law firm has already provided legal advice to the biotech company on several occasions in connection with capital measures. CapSolutions GmbH and MC Services AG also participated in the transaction as bookrunners. Baader Bank AG was responsible for the technical implementation of the capital increase.

Advisors Medigene AG

GÖRG Partnerschaft von Rechtsanwälten mbB

Dr Bernt Paudtke (Lead Partner, Stock Corporation and Capital Markets / Corporate Law, Munich)

Dr Lutz Pospiech (Partner, stock corporation and capital markets law / corporate law, Munich)

Dr Stefan Heyder (Partner, Corporate Law, Munich)

Tobias Reichenberger (Associated Partner, Stock Corporation and Capital Markets / Corporate Law, Munich)

Your contact at GÖRG

Dr Bernt Paudtke

Phone +49 89 309 0667 29, E-Mail: bpaudtke@goerg.de

Communications & Marketing

Christine Ström

Phone +49 40 500360 145, E-Mail: cstroem@goerg.de

About GÖRG

GÖRG is one of Germany's leading and independent business law firms.

With around 350 lawyers and tax advisors in Berlin, Cologne, Frankfurt am Main, Hamburg and Munich, we advise well-known domestic and foreign businesses from all areas of industry, banking, real estate, trade, media and services on all core areas of business law.

Our Offices

GÖRG Partnerschaft von Rechtsanwälten mbB

BERLIN

Kantstr. 164,
10623 Berlin
Phone +49 30 884503-0
Fax +49 30 882715-0

HAMBURG

Alter Wall 20 - 22,
20457 Hamburg
Phone +49 40 500360-0
Fax +49 40 500360-99

FRANKFURT AM MAIN

Ulmenstr. 30,
60325 Frankfurt am Main
Phone +49 69 170000-17
Fax +49 69 170000-27

COLOGNE

Kennedyplatz 2,
50679 Köln
Phone +49 221 33660-0
Fax +49 221 33660-80

MUNICH

Prinzregentenstr. 22,
80538 München
Phone +49 89 3090667-0
Fax +49 89 3090667-90